NCT02319148View on ClinicalTrials.gov

A Study to Estimate the Effect of CYP3A4 Inhibitors (Itraconazole, Diltiazem or Verapamil) on the Pharmacokinetics of Single Dose PF- 00489791 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions
Healthy Volunteers
Interventions
DRUG

itraconazole

itraconazole dosed at 200 mg

DRUG

diltiazem

diltiazem dosed at 240 mg

DRUG

SR verapamil

SR verapamil dosed at 240 mg

DRUG

PF-00489791

PF-00489791 20 mg single dose administration

Trial Locations (1)

B-1070

Pfizer Clinical Research Unit, Brussels

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT02319148 - A Study to Estimate the Effect of CYP3A4 Inhibitors (Itraconazole, Diltiazem or Verapamil) on the Pharmacokinetics of Single Dose PF- 00489791 in Healthy Volunteers | Biotech Hunter | Biotech Hunter